SGLT2 inhibitors clinically beneficial in patients with gout, suggests review
USA: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors may provide improved outcomes in treating gout and its common comorbidities, a recent review has shown. SGLT2 inhibitors are a popular drug class in the management of cardiometabolic and diabetic conditions. The review, published in Nature Reviews Rheumatology, suggested that the mechanism of SGLT2 inhibition in patients with […]